MyoKardia Inc. (NASDAQ:MYOK) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $20.00 and last traded at $18.54, with a volume of 48,795 shares changing hands. The stock had previously closed at $18.59.

A number of research analysts recently commented on the stock. Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $20.00 price target (up previously from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of MyoKardia in a report on Thursday, May 12th. BMO Capital Markets assumed coverage on shares of MyoKardia in a report on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Cowen and Company reaffirmed a “buy” rating on shares of MyoKardia in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $23.50.

The stock has a 50 day moving average of $15.30 and a 200 day moving average of $11.75. The stock’s market capitalization is $504.59 million.

MyoKardia (NASDAQ:MYOK) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $3.55 million for the quarter, compared to analyst estimates of $3.55 million. MyoKardia’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts forecast that MyoKardia Inc. will post ($1.53) EPS for the current year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.